Live CE

RACE-approved CE for veterinarians and veterinary technicians

Verdinexor: A New Oral Treatment Option for Canine Lymphoma

Live and On Demand

Presented by: Dr. David Bruyette, Dan Dreyfuss, Julie Dinnage, Jim Lowe

Verdinexor: A New Oral Treatment Option for Canine Lymphoma

Live and On Demand

In this CE session, we’ll review the latest best practices for managing canine lymphoma. We’ll also talk about how the first FDA conditionally approved oral tablet for canine lymphoma, LAVERDIA™-CA1 (verdinexor), is giving veterinarians and dog owners more options and increasing access to cancer care.

Presented by: Dr. David Bruyette, Dan Dreyfuss, Julie Dinnage, Jim Lowe

Background Image

Verdinexor: A New Oral Treatment Option for Canine Lymphoma

November 23, 2021 2:00 AM UTC

On-Demand CE

RACE-approved CE for veterinarians and veterinary technicians

The Science Behind SINE Class Drugs

Novel Small Molecules for Oncology

Presented by: Dr. David Bruyette

The Science Behind SINE Class Drugs

Novel Small Molecules for Oncology

Selective inhibition of nuclear export (SINE) class drugs are small molecules recently introduced to both human and veterinary oncology. This course explores how SINE drugs introduce new ways to think about managing cancer and how they may be integrated into the treatment of several neoplastic diseases.

Presented by: Dr. David Bruyette

Background Image

Verdinexor: A New Oral Treatment Option for Canine Lymphoma

Presented by: Dr. David Bruyette